ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
OPINION
The prospects of gene therapy for mitochondrial diseases: can’t we do without CRISPR/Cas9?
About authors
1 Faculty of Biology, Lomonosov Moscow State University, Moscow
2 Laboratory of Molecular Genetics, Genomics and Microbiology,University of Strasbourg, Strasbourg, France
3 Institute of Living Systems,Immanuel Kant Baltic Federal University, Kaliningrad, Russia
Correspondence should be addressed: Peter Kamenski
Leninskie Gory, d. 1, str. 12, Moscow, Russia, 119991 (Faculty of Biology); ur.usm.oib.nietorp@retep
About paper
Funding: Russian Science Foundation, grant No. 14-50-00029 (Lomonosov Moscow State University); Project 5–100 of the Ministry of Education and Science of the Russian Federation (Immanuel Kant Baltic Federal University); the International Associated Laboratory RNA-mitocure (Lomonosov Moscow State University and the University of Strasbourg).
Contribution of the authors to this work: Chicherin IV, Levitsky SA —analysis of literature; Krasheninnikov IA, Tarassov I — analysis of mechanism of a hypothetical mitoCRISPR/Cas9 platform; Kamenski P — data generalization, drafting of a manuscript. All authors participated in editing of the manuscript.
Received: 2017-06-20
Accepted: 2017-06-23
Published online: 2017-07-19
|
No data available...